Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Recipient : SparX Biopharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement
SparX Biopharma Signs Research Deal with Mitsubishi Tanabe for ADCs
Details : The SparX research with MTPA will focus on an ADC against a first-in-class immune cell target, with the potential to serve as a universal tumor-targeting strategy across multiple cancer types.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
May 15, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Recipient : SparX Biopharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement
Reset All
